---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-23-004701"
form_type: "8-K"
ticker: "VCEL"
cik: "0000887359"
company_name: "Vericel Corp"
filed_at: "2023-02-23T23:59:59+00:00"
generated_at: "2026-06-19T03:47:16.659151+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Vericel Q4 revenue $52.7M record; net income up 31%; 2023 guidance $180-188M

## Summary
- Q4 total revenue $52.7M (+11% YoY); MACI revenue $46.3M (+24% YoY); Epicel $6.3M.
- Q4 net income $5.9M ($0.12 diluted) vs $4.5M ($0.09) a year ago; adjusted EBITDA $14.9M (28% margin).
- Full-year 2022 total revenue $164.4M; net loss $16.7M ($0.35 diluted); adjusted EBITDA $24.2M (15% margin).
- 2023 guidance: total revenue $180-188M, MACI $152-156M, burn care $28-32M, gross margin high-60%.
- FDA approved NexoBrid for eschar removal; U.S. commercial launch expected Q2 2023; arthroscopic MACI on track for 2024.

## SEC filing metadata
- accession: 0001628280-23-004701
- form_type: 8-K
- ticker: VCEL
- cik: 0000887359
- company_name: Vericel Corp
- filed_at: 2023-02-23T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/887359/000162828023004701/0001628280-23-004701-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/887359/000162828023004701/vcel-20230223.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-23-004701
- JSON: https://secwatch.observer/filing/0001628280-23-004701.json
- Plain text: https://secwatch.observer/filing/0001628280-23-004701.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.